RBC Capital analyst Gregory Renza lowered the firm’s price target on Amgen to $258 from $268 and keeps a Sector Perform rating on the shares. The company’s Q4 results were largely as expected, highlighting the steady execution of its commercial portfolio, the analyst tells investors in a research note. The firm added however that the focus for Amgen will be on its first half close of the Horizon Therapeutics (HZNP) acquisition. RBC also updates its model to reflect the company’s year-end updates and "several pushes and pulls on the forecast" around its revenue price/volume mix, tax rate, FY23 guidance, and the management’s path to 2030 targets.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on AMGN:
- Amgen price target lowered to $253 from $276 at BMO Capital
- Amgen price target lowered to $289 from $307 at Cowen
- Amgen price target lowered to $220 from $240 at Credit Suisse
- Amgen price target lowered to $230 from $240 at Barclays
- Amgen, Horizon Therapeutics receive second request for additional info from FTC